Loading clinical trials...
Loading clinical trials...
A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy and to Determine the Pharmacokinetics of Two Doses of AVP-923 (Dextromethorphan/Quinidine) in the Treatment of Pseudobulbar Affect (PBA) in Patients With Amyotrophic Lateral Sclerosis (ALS) and Multiple Sclerosis (MS)
Conditions
Interventions
dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg
dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg
+1 more
Locations
62
United States
St. Joseph's Hospital and Medical Center
Phoenix, Arizona, United States
Neuromuscular Research Center
Scottsdale, Arizona, United States
South Coast Clinical Trials
Anaheim, California, United States
UCI Medical Center
Irvine, California, United States
Center for Neurologic Study
La Jolla, California, United States
UCLA School of Medicine
Los Angeles, California, United States
Start Date
December 1, 2007
Primary Completion Date
June 1, 2009
Completion Date
September 1, 2009
Last Updated
April 12, 2017
Lead Sponsor
Avanir Pharmaceuticals
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions